Table 1. Patient characteristics.
| Characteristic | Data |
|---|---|
| Age at diagnosis | Median 64 yo (25–84 yo) |
| Baseline BMI | Median 26.1 (18.1–46.1) |
| Age | |
| <50 yo | 7 (7.1%) |
| >50 yo | 91 (92.9%) |
| Gender | |
| Male | 58 (59.2%) |
| Female | 40 (40.8%) |
| ECOG PS at diagnosis | |
| 0 | 13 (15.9%) |
| 1 | 56 (68.3%) |
| 2–3 | 13 (15.9%) |
| Race | |
| Caucasian | 73 (74.5%) |
| Non-Caucasian | 25 (25.5%) |
| Metastatic disease sites | |
| Diffuse | 55 (56.1%) |
| Single organ | 43 (43.9%) |
| 1st Line therapy | |
| FOLFIRINOX | 34 (34.7%) |
| Gemcitabine + nab-paclitaxel | 57 (58.2%) |
| Gemcitabine + cisplatin | 2 (2.0%) |
| 5-FU +/− oxaliplatin | 1 (1.0%) |
| Gemcitabine +/− erlotinib | 3 (3.1%) |
| Trial | 1 (1.0%) |
| CA19-9 at diagnosis | |
| <35 | 9 (10.3%) |
| <59× ULN | 38 (43.7%) |
| >59× ULN | 40 (46.0%) |
| Second-line therapy received | |
| Yes | 65 (66.3%) |
| No | 33 (33.7%) |
| CA19-9 at first-line progression | |
| <35 | 8 (8.9%) |
| <59× ULN | 34 (37.8%) |
| >59× ULN | 48 (53.3%) |
| Second-line therapy | |
| None | 33 (33.7%) |
| Gemcitabine + nab-paclitaxel | 31 (31.6%) |
| FOLFIRINOX | 8 (8.2%) |
| 5-FU +/− oxaliplatin | 8 (8.2%) |
| 5-FU + irinotecan or liposomal irinotecan | 3 (3.1%) |
| Gemcitabine based therapy | 12 (12.3%) |
| Other | 3 (3.1%) |
| Second-line therapy radiographic results | |
| Disease-control | 18 (27.7%) |
| Progression | 47 (72.3%) |
ECOG, Eastern Cooperative Oncology Group; PS, performance status.